Empowering Oncology Decisions
DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.
GCC Tests for Colorectal Cancer
DiagnoCure has acquired diagnostic rights to the GCC marker with utility in colorectal cancer and intends to launch the first GCC test in 2008.
Previstage™ GCC Colorectal Staging Test »
GCC colorectal cancer monitoring test »
PCA3 Molecular Marker
The PCA3 test for prostate cancer is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay.
Special Media Coverage on PCA3 »
External site on PCA3, Ismar Healthcare »
Shc Proteins for Breast, Colon and
other Cancers
On August 2007, DiagnoCure acquired lead proprietary prognostic tests with applications in five tumor types, including breast and colon.
INVESTORS
|
2.95
-0.04
|
Open: 2.96
$CAN.
Quotes are delayed. |
- Second quarter 2008 (PDF)
- Corporate Fact Sheet (PDF)
- Corporate Brochure (PDF)
- 2007 Annual Report (PDF)
the Undy 5000 Run for
the fight of colon cancer
September 27, 2008 in PhiladelphiaLatest News
June 26, 2008 - DiagnoCure appoints Vice President, Marketing and National Sales
June 13, 2008 - DiagnoCure announces second quarter 2008 results
Upcoming Events
September 25 - 28, 2008
College of American Pathologists Annual Meeting
San Diego, CA, USA
October 30 - November 2, 2008
Association for Molecular Pathology 2008 Annual Meeting
Dallas, TX, USA